PURPOSE: With novel therapies including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs), healthcare providers (HCPs) face complexities managing treatment for patients with relapsed/refractory multiple myeloma (RRMM). This study, among the largest surveys on RRMM, examined unmet needs in care access, barriers to novel therapy use, and treatment decision-making. METHODS: This survey-based study (March-June 2024) enrolled 2284 participants (patients: 1301
HCPs: 983) across 7 countries. Patients with >
1 relapse/progression and HCPs managing ≥3 patients were included. Data were analyzed using descriptive statistics and Χ RESULTS: For patients, treatment priorities included slowing disease progression (second line [2L], 47%
third or later line [≥3L], 49%), minimizing adverse events (AEs
2L, 43%
≥3L, 49%), and extending life (2L, 39%
≥3L, 38%). HCPs prioritized prolonging survival and controlling disease. Younger patients (<
65 vs ≥65 years) prioritized convenience (40% vs 24%
CONCLUSION: This study revealed gaps in treatment priorities
patients valued quality of life and AE management, while HCPs focused on efficacy and delaying progression. There is a significant need to educate HCPs and patients on the impact of shared decision-making when considering novel treatments for RRMM.